应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
KLRA Kailera Therapeutics, Inc.
已收盘 06-03 16:00:00 EDT
22.38
-0.21
-0.93%
盘后
22.38
+0.00
0.00%
16:55 EDT
最高
23.23
最低
22.02
成交量
42.23万
今开
22.44
昨收
22.59
日振幅
5.36%
总市值
28.99亿
流通市值
10.05亿
总股本
1.30亿
成交额
954.34万
换手率
0.94%
流通股本
4,492万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Kailera Therapeutics 公布 HRS-7535 三期与 HRS-4729 一期试验积极顶线数据
美股速递 · 05-27
Kailera Therapeutics 公布 HRS-7535 三期与 HRS-4729 一期试验积极顶线数据
Kailera Therapeutics获Leerink Partners首次覆盖,给予“跑赢大盘”评级,目标价36美元
美股速递 · 05-12
Kailera Therapeutics获Leerink Partners首次覆盖,给予“跑赢大盘”评级,目标价36美元
减肥药企业Kailera纳斯达克上市:市值31亿美元 恒瑞医药成大赢家
雷递网 · 04-19
减肥药企业Kailera纳斯达克上市:市值31亿美元 恒瑞医药成大赢家
异动解读 | 凯莱拉治疗公司盘中大涨62.5%,受益于纳斯达克成功上市及减肥药市场广阔前景
异动解读 · 04-18
异动解读 | 凯莱拉治疗公司盘中大涨62.5%,受益于纳斯达克成功上市及减肥药市场广阔前景
美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%
智通财经 · 04-18
美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%
募资6.25亿美元创五年之最 减肥药新贵Kailera Therapeutics(KLRA.US)今晚登陆纳斯达克
智通财经 · 04-17
募资6.25亿美元创五年之最 减肥药新贵Kailera Therapeutics(KLRA.US)今晚登陆纳斯达克
减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克
智通财经 · 04-14
减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克
加载更多
公司概况
公司名称:
Kailera Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Kailera Therapeutics, Inc.于2024年5月8日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物技术公司,致力于通过推进多元化的研发管线,引领肥胖症治疗的新时代。目前,该公司正在快速推进四款处于临床阶段的候选产品,这些产品利用多种基于胰高血糖素样肽-1 (GLP-1) 的作用机制和给药途径。
发行价格:
--
{"stockData":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics, Inc.","latestPrice":22.38,"timestamp":1780516800000,"preClose":22.59,"halted":0,"volume":422326,"hourTrading":{"tag":"盘后","latestPrice":22.38,"preClose":22.38,"latestTime":"16:55 EDT","volume":1830,"amount":40952.28,"timestamp":1780520130729,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.009296148738379853,"floatShares":44921899,"shares":129537300,"eps":-1.204378,"marketStatus":"已收盘","change":-0.21,"latestTime":"06-03 16:00:00 EDT","open":22.44,"high":23.23,"low":22.02,"amount":9543359.74764,"amplitude":0.053564,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.204378,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780560000000},"marketStatusCode":5,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":22.59,"preHourTrading":{"tag":"盘前","latestPrice":22.48,"preClose":22.59,"latestTime":"09:29 EDT","volume":169,"amount":3792.9295300000003,"timestamp":1780493399999,"change":-0.11,"changeRate":-0.004869,"amplitude":0.016379},"postHourTrading":{"tag":"盘后","latestPrice":22.38,"preClose":22.38,"latestTime":"16:55 EDT","volume":1830,"amount":40952.28,"timestamp":1780520130729,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.970643},"requestUrl":"/m/hq/s/KLRA","defaultTab":"news","newsList":[{"id":"1141920352","title":"Kailera Therapeutics 公布 HRS-7535 三期与 HRS-4729 一期试验积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1141920352","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141920352?lang=zh_cn&edition=full","pubTime":"2026-05-27 04:08","pubTimestamp":1779826103,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics 宣布,其候选药物 HRS-7535 的三期临床试验以及 HRS-4729 的一期临床试验均取得了积极的顶线数据结果。这一进展标志着公司在相关治疗领域的研发取得了重要突破,为后续的临床开发与监管申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195378546","title":"Kailera Therapeutics获Leerink Partners首次覆盖,给予“跑赢大盘”评级,目标价36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195378546","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195378546?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:11","pubTimestamp":1778580703,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布,对生物制药公司Kailera Therapeutics启动研究覆盖。该机构给予该公司股票“跑赢大盘”的初始评级,并设定了每股36美元的目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628766952","title":"减肥药企业Kailera纳斯达克上市:市值31亿美元 恒瑞医药成大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2628766952","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628766952?lang=zh_cn&edition=full","pubTime":"2026-04-19 15:45","pubTimestamp":1776584754,"startTime":"0","endTime":"0","summary":"减肥药企业Kailera Therapeutics(股票代码:“KLRA”)日前在美国纳斯达克上市,发行价为16美元,发行3906万股,募资总额为6.24亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33340/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK0188","LU2580892862.HKD","LU2488822045.USD","LU0359201885.HKD","LU0359201612.USD","QID","BK0239","BK1147","GPIQ","LU1255011170.USD","LU2097828805.USD","TQQQ","LU1328615791.USD","QQQJ","LU2097828557.USD","LU2328871848.SGD","QDTE","QYLG","QLD","LU1997244956.HKD","LU1655091616.SGD","LU1146622755.USD","BK0028","ONEQ","LU2495084118.USD","600276","LU2097828631.EUR","IYW","BK0012","NVIW.SI","LU2148510915.USD","LU1969619763.USD","QQQM","SQQQ","LU1997245177.USD","LU1064130708.USD","KLRA","LU0359202008.SGD","LU0405327148.USD","LU1064131003.USD","BK1191","LU1997245094.SGD","MNQmain","TQQY","QQQ","BK0060","NQmain","LU2289578879.USD","LU2097828474.EUR","LU1023057109.AUD","QQQE","QQQA","LU1820825898.SGD","LU2543165471.USD","BK0196","BK0183","LU2097828714.EUR","PSQ","QQQY","FTEC","LU1580142542.USD","01276","LU1781817850.SGD","BK4007","LU2580892789.USD","JEPQ","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136289592","title":"异动解读 | 凯莱拉治疗公司盘中大涨62.5%,受益于纳斯达克成功上市及减肥药市场广阔前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1136289592","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136289592?lang=zh_cn&edition=full","pubTime":"2026-04-18 01:27","pubTimestamp":1776446849,"startTime":"0","endTime":"0","summary":"凯莱拉治疗公司今日盘中股价大幅上涨62.50%,引起了市场的广泛关注。此次股价大涨与公司成功登陆纳斯达克密切相关。消息显示,凯莱拉治疗公司首次公开募股以每股16美元的价格发行,而市场预期其开盘价将达到32美元,远高于发行价,这反映了投资者对公司的高度认可和强烈兴趣。凯莱拉治疗公司的主要候选产品ribupatide作为一种每周注射一次的GLP-1药物,目前正处于后期试验阶段,这进一步增强了市场对其未来商业化前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628578522","title":"美股异动 | 减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场 开盘暴涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628578522","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628578522?lang=zh_cn&edition=full","pubTime":"2026-04-18 00:00","pubTimestamp":1776441606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周五,减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场,开盘暴涨超50%,报24.1美元,IPO价格为16美元。该公司创下2021年以来美国生物科技领域规模最大的IPO纪录。Kailera成立于2024年,是一家处于临床后期的生物科技公司,正在开发四种基于GLP-1的减肥药物,其中包括一款每周注射一次的药物和一款每日口服一次的药片,目前均已进入后期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4139","KLRA","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221198","title":"募资6.25亿美元创五年之最 减肥药新贵Kailera Therapeutics(KLRA.US)今晚登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221198","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221198?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:33","pubTimestamp":1776396818,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,专注于肥胖症治疗的临床阶段生物科技公司Kailera Therapeutics Inc.通过扩大首次公开发行规模,成功募资6.25亿美元,创下2021年以来美国生物科技领域规模最大的IPO纪录。根据周四发布的一份声明,Kailera以每股16美元的价格出售了约3900万股股票。包括贝恩资本旗下Bain Capital Private Equity、Bain Capital Life Sciences和卡塔尔投资局在内的现有股东已表示,有意按IPO价格合计购买最多2.25亿美元的公司股票。此次IPO之前,Kailera已于去年10月通过B轮融资募资6亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KLRA","QQQY","QDTE","PSQ","QQQ","ONEQ","FTEC","MNQmain","NVIW.SI","BK1147","QQQM","BK4539","JEPQ","TQQQ","BK4139","BK4007","QID","QQQE","IYW","GPIQ","SQQQ","QQQA","QYLG","TQQY","QLD","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627741817","title":"减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2627741817","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627741817?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:19","pubTimestamp":1776151188,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics于周一公布其首次公开募股条款。根据计划,Kailera 预计将于本周四晚间完成最终定价,并于次日在纳斯达克交易所挂牌交易。其核心候选药物ribupatide目前正在全球开展III期临床试验,这是一种每周一次注射的GLP-1/葡萄糖依赖性促胰岛素多肽受体双重激动剂肽。Kailera Therapeutics成立于2024年,计划在纳斯达克上市,股票代码为KLRA。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONEQ","QQQE","KLRA","JEPQ","QDTE","BK4539","TQQY","QQQY","BK1147","IYW","MNQmain","FTEC","QQQJ","TQQQ","BK4007","QYLG","QQQA","PSQ","QID","QLD","QQQ","QQQM","GPIQ","SQQQ","BK4139","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.kailera.com","stockEarnings":[{"period":"1week","weight":0.0473},{"period":"1month","weight":-0.1018},{"period":"3month","weight":0.4119},{"period":"ytd","weight":0.4119}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kailera Therapeutics, Inc.于2024年5月8日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物技术公司,致力于通过推进多元化的研发管线,引领肥胖症治疗的新时代。目前,该公司正在快速推进四款处于临床阶段的候选产品,这些产品利用多种基于胰高血糖素样肽-1 (GLP-1) 的作用机制和给药途径。","exchange":"NASDAQ","name":"Kailera Therapeutics, Inc.","nameEN":"Kailera Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kailera Therapeutics, Inc.(KLRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kailera Therapeutics, Inc.(KLRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kailera Therapeutics, Inc.,KLRA,Kailera Therapeutics, Inc.股票,Kailera Therapeutics, Inc.股票老虎,Kailera Therapeutics, Inc.股票老虎国际,Kailera Therapeutics, Inc.行情,Kailera Therapeutics, Inc.股票行情,Kailera Therapeutics, Inc.股价,Kailera Therapeutics, Inc.股市,Kailera Therapeutics, Inc.股票价格,Kailera Therapeutics, Inc.股票交易,Kailera Therapeutics, Inc.股票购买,Kailera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kailera Therapeutics, Inc.(KLRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kailera Therapeutics, Inc.(KLRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}